This is a routine clinical milestone for a micro-cap biotech — IRB approvals for Phase I/II continuation are common and do not constitute a value inflection. Monitor for actual dosing data or safety readouts from Parts B/C, which would be more material. The company's extremely low share count (158K shares) means any equity offering would be highly dilutive — watch for capital raises.
Price Chart
Executive Summary
Clearmind Medicine announced that the Johns Hopkins IRB approved advancing its Phase I/II CMND-100 trial to Parts B and C, following successful completion of earlier stages. For a $2M market-cap pre-revenue biotech, this is a modest clinical milestone that de-risks the program incrementally but does not change the fundamental risk profile or cash runway.
Key Facts
- Johns Hopkins Medicine IRB granted approval to proceed with Parts B and C of the CMND-100 Phase I/II clinical trial for Alcohol Use Disorder
- The trial is titled 'A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and AUD Subjects: Parts A, B, and C'
- No financial terms, enrollment numbers, dosing data, or timeline for completion were disclosed
- Company had 158,076 common shares outstanding as of January 19, 2026, per the 20-F filed January 2026
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company with $2M market cap
Risk Factors
- No disclosed cash runway or financing plans — company may need to raise capital to fund Parts B and C
- Clinical-stage biotech with no approved products or revenue; any safety signal could halt the program
- Extremely low market cap ($2M) and share count (158K) make the stock highly volatile and susceptible to dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-060791 |
| Document: ea029214102ex99-1.htm | 0001213900-26-060791 |
| Document: 0001213900-26-060791-index-headers.html | 0001213900-26-060791 |
| Document: 0001213900-26-060791-index.html | 0001213900-26-060791 |
| Document: 0001213900-26-060791.txt | 0001213900-26-060791 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.87 (+2.17%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $5.87 (−5.78%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.87 (−14.48%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.87 (+521.82%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $5.87 (+469.90%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $5.87 (−406.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers